Germany’s Merck KGaA (MRK: DE) has regained exclusive worldwide rights to develop, manufacture, and commercialize its checkpoint blocker Bavencio (avelumab).
The news comes just a couple of weeks after erstwhile co-developer Pfizer (NYSE: PFE) announced plans to buy antibody-drug conjugate (ADC) company Seagen (Nasdaq: SGEN), at a price of $43 billion.
That acquisition was likely to require the divestment of Pfizer’s interests in Bavencio in order to satisfy antitrust bodies, given the overlap with Seagen’s Padcev (enfortumab vedotin-ejfv), a first-in-class ADC approved in bladder cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze